High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy

BACKGROUND: CD16-chimeric antigen receptors (CAR) T cells recognise the Fc-portion of therapeutic antibodies, which can enable the selective targeting of different antigens. Limited evidence exists as to which CD16-CAR design and antibody partner might be most effective. We have hypothesised that th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Rataj, Felicitas, Jacobi, Severin J., Stoiber, Stefan, Asang, Florian, Ogonek, Justyna, Tokarew, Nicholas, Cadilha, Bruno L., van Puijenbroek, Erwin, Heise, Constanze, Duewell, Peter, Endres, Stefan, Klein, Christian, Kobold, Sebastian
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6325122/
https://ncbi.nlm.nih.gov/pubmed/30429531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0341-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars